Chen Jie, Chen Yong-Jian, Jiang Nan, Xu Jian-Liang, Liang Zi-Ming, Bai Ming-Jun, Xing Yan-Fang, Liu Zhuo, Wu Xiang-Yuan, Li Xing
Department of Medical Oncology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China.
Department of Guangdong Key Laboratory of Liver Disease, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China.
Oncologist. 2021 Aug;26(8):e1434-e1444. doi: 10.1002/onco.13743. Epub 2021 Mar 24.
The purpose of this study was to investigate the predictive capability of neutrophil-to-apolipoprotein A1 ratio (NAR) for predicting overall survival (OS) among patients with hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE).
We investigated the clinical features of 554 patients with HCC receiving TACE and assessed NAR's predictive value for OS with 222 patients (the discovery cohort) and 332 patients (the validation cohort). The association of NAR with circulation lectin-type oxidized low-density lipoprotein receptor-1-positive (LOX-1 ) polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) was illustrated.
Multivariate Cox regression revealed that lymphocyte count; Tumor, Node, Metastasis (TNM) stage; and NAR were independent prognostic factors in the discovery cohort. The validation cohort confirmed the independent prognostic value of TNM stage and NAR. Patients with low NAR (<2.7) displayed significantly increased OS in the discovery cohort (59.8 months vs. 21 months), the validation group (38.0 months vs. 23.6 months), and the total cohort (44.1 months vs. 22.0 months). A Cox proportional hazards model was used to combine Cancer of the Liver Italian Program (CLIP) score with discretized NAR. C-index illustrated that NAR-integrated CLIP score was the best model compared with NAR and CLIP score. Furthermore, NAR-CLIP presented superior predictive capacity for 10-, 20-, 30-, 40-, 50-, and 60-month survival compared with CLIP score by survival receiver-operator characteristic analysis in the discovery cohort, validation cohort, and total cohort. NAR was significantly associated with LOX-1 PMN-MDSCs by linear regression.
This study identified NAR as an independent predictor for OS among patients with HCC receiving TACE. NAR reflected circulation LOX-1 PMN-MDSC level.
The present study identified neutrophil-to-apolipoprotein A1 ratio (NAR) as an independent predictor for overall survival among patients with hepatocellular carcinoma receiving transarterial chemoembolization. NAR reflected circulation level of lectin-type oxidized low-density lipoprotein receptor-1-positive polymorphonuclear myeloid-derived suppressor cells.
本研究旨在探讨中性粒细胞与载脂蛋白A1比值(NAR)对接受经动脉化疗栓塞术(TACE)的肝细胞癌(HCC)患者总生存期(OS)的预测能力。
我们调查了554例接受TACE的HCC患者的临床特征,并评估了NAR对222例患者(发现队列)和332例患者(验证队列)OS的预测价值。阐述了NAR与循环凝集素型氧化低密度脂蛋白受体-1阳性(LOX-1)多形核髓源性抑制细胞(PMN-MDSCs)的关联。
多变量Cox回归显示,淋巴细胞计数、肿瘤-淋巴结-转移(TNM)分期和NAR是发现队列中的独立预后因素。验证队列证实了TNM分期和NAR的独立预后价值。低NAR(<2.7)的患者在发现队列(59.8个月对21个月)、验证组(38.0个月对23.6个月)和总队列(44.1个月对22.0个月)中的OS显著延长。使用Cox比例风险模型将意大利肝癌项目(CLIP)评分与离散化的NAR相结合。C指数表明,与NAR和CLIP评分相比,NAR整合CLIP评分是最佳模型。此外,通过生存接受者操作特征分析,在发现队列、验证队列和总队列中,NAR-CLIP在预测10、20、30、40、50和60个月生存率方面比CLIP评分具有更高的预测能力。通过线性回归分析,NAR与LOX-1 PMN-MDSCs显著相关。
本研究确定NAR是接受TACE的HCC患者OS的独立预测指标。NAR反映了循环LOX-1 PMN-MDSC水平。
本研究确定中性粒细胞与载脂蛋白A1比值(NAR)是接受经动脉化疗栓塞术的肝细胞癌患者总生存期的独立预测指标。NAR反映了凝集素型氧化低密度脂蛋白受体-1阳性多形核髓源性抑制细胞的循环水平。